They only need to be successful on one endpoint and the FDA will approve it. They also had control over the patients they enrolled in this study and they seem to have done what worked for phase 2. I'm really hoping for some good news and feel about 80% sure the data will pass for the FDA needs. All IMO, but the company seems confident and I do like the insiders acquiring shares as well as institutes.
News 
Market Data 
Discover 
